CART-19 Cells For MRD Positive CD19+ ALL

Summary

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Timeline

Start

2016-11

Primary completion

2019-12

Completion

2020-12

Drugs

Indications